ARCHIVES

Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.

This article is from The Cancer Letter archive.

Vol. 32 No. 42 | November 22, 2006

Download PDF Visit The Full Archive

Related Articles

Two OAM Advisors Criticize Third over ACS Membership

July 23, 1993

In Brief: House Cuts NCI Rescission To $7.73 Million; Weinhuse, Ultmann New ACCR, ASCO Presidents

May 8, 1981

NCI Plans $61 Million For Six-Year Program In Biomarker Research For Early Detection

December 4, 1998

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

L-PAM Benefit To Post-Menopausal Patients Challenged

October 29, 1976

Funding Opportunities

October 25, 2002